Kurt, Ibrahim C. http://orcid.org/0000-0003-3927-0991
Zhou, Ronghao http://orcid.org/0000-0002-3917-0694
Iyer, Sowmya
Garcia, Sara P. http://orcid.org/0000-0003-3312-6454
Miller, Bret R. http://orcid.org/0000-0002-9872-4642
Langner, Lukas M. http://orcid.org/0000-0003-4658-9829
Grünewald, Julian http://orcid.org/0000-0001-7537-7505
Joung, J. Keith http://orcid.org/0000-0001-5630-5645
Funding for this research was provided by:
Boehringer Ingelheim Fonds MD fellowship
Deutsche Forschungsgemeinschaft (416375182)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (RM1 HG009490)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35 GM118158)
United States Department of Defense | Defense Advanced Research Projects Agency (HR0011-17-2-0042)
Article History
Received: 17 October 2019
Accepted: 19 June 2020
First Online: 20 July 2020
Competing interests
: J.K.J. has financial interests in Beam Therapeutics, Editas Medicine, Excelsior Genomics, Pairwise Plants, Poseida Therapeutics, Transposagen Biopharmaceuticals and Verve Therapeutics (f/k/a Endcadia). J.K.J.’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. J.K.J. is a member of the Board of Directors of the American Society of Gene and Cell Therapy. J.G., I.C.K., R.Z. and J.K.J. are coinventors on patent applications that have been filed by Partners Healthcare/Massachusetts General Hospital on engineered C-to-G transversion base editors and other related base editor technologies.